Japan Approval strengthened fundamentals. Given Japan market reach endorsing future revenues, soon market valuation will sync-in and the rally should kick in and here are the Fibonacci levels for each leg.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.421 CHF
−46.99 M CHF
301.81 M CHF
196.99 M
About Esperion Therapeutics, Inc.
Sector
Industry
CEO
Sheldon L. Koenig
Website
Headquarters
Ann Arbor
Founded
1998
ISIN
US29664W1053
FIGI
BBG00LVD9YR7
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Related stocks
$ESPRNot financial advice.
NASDAQ:ESPR weekly chart
working is way up to the top of this broadening formation. more likely to fill gap on purple box.
Like and follow.
Thanks.
ESPR BULLISHEsperion Therapeutics (NASDAQ: ESPR), priced at $1.68 as of September 27, focuses on creating medications for cardiovascular and cardiometabolic diseases. They've launched products like NEXLETOL and NEXLIZET, which help lower LDL cholesterol in adults. Recently, 26 hedge funds held about $98.59 mill
ESPR - Momentum Biotech PlayEsperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializi
ESPR - Approval of NEXLETOL (Cardiovascular Diseases)Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializi
ESPR a penny and medtech stock LONGESPR on the 120-minute chart is surging with momentum from an FDA approval for a new
cholestrol and lipid medication which will be an alternative to the at statin class which has
side effects and can cause diabetes. I am familar with a few of the professionals on the
science advisory board they a
$ESPR Esperion Therapeutics Inc. NASDAQ:ESPR Esperion Therapeutics Inc.
Long term PTs 39 - 53 - 76 and higher
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempe
Esperion Therapeutics@KalaGhazi
Esperion Therapeutics
Big drop yesterday.
Will it rally or back down again???
ESPR (Esperion Therapeutics) short positionESPR (Esperion Therapeutics) short position
Entry level: $7.93
Take profit: $6.82
Stop loss: $8.48
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0ET is 1.924 CHF — it has decreased by −14.34% in the past 24 hours. Watch Esperion Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Esperion Therapeutics, Inc. stocks are traded under the ticker 0ET.
0ET stock has risen by 188.02% compared to the previous week, the month change is a 188.02% rise, over the last year Esperion Therapeutics, Inc. has showed a 34.92% increase.
We've gathered analysts' opinions on Esperion Therapeutics, Inc. future price: according to them, 0ET price has a max estimate of 12.72 CHF and a min estimate of 1.27 CHF. Watch 0ET chart and read a more detailed Esperion Therapeutics, Inc. stock forecast: see what analysts think of Esperion Therapeutics, Inc. and suggest that you do with its stocks.
0ET stock is 16.74% volatile and has beta coefficient of 1.89. Track Esperion Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Esperion Therapeutics, Inc. there?
Today Esperion Therapeutics, Inc. has the market capitalization of 426.01 M, it has decreased by −11.39% over the last week.
Yes, you can track Esperion Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Esperion Therapeutics, Inc. is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
0ET earnings for the last quarter are −0.02 CHF per share, whereas the estimation was −0.12 CHF resulting in a 86.27% surprise. The estimated earnings for the next quarter are 0.02 CHF per share. See more details about Esperion Therapeutics, Inc. earnings.
Esperion Therapeutics, Inc. revenue for the last quarter amounts to 65.36 M CHF, despite the estimated figure of 50.02 M CHF. In the next quarter, revenue is expected to reach 73.75 M CHF.
0ET net income for the last quarter is −10.10 M CHF, while the quarter before that showed −35.81 M CHF of net income which accounts for 71.81% change. Track more Esperion Therapeutics, Inc. financial stats to get the full picture.
No, 0ET doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 30, 2025, the company has 304 employees. See our rating of the largest employees — is Esperion Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Esperion Therapeutics, Inc. EBITDA is −28.04 M CHF, and current EBITDA margin is 16.39%. See more stats in Esperion Therapeutics, Inc. financial statements.
Like other stocks, 0ET shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Esperion Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Esperion Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Esperion Therapeutics, Inc. stock shows the buy signal. See more of Esperion Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.